跳至主要内容
临床试验/CTRI/2018/06/014478
CTRI/2018/06/014478尚未招募未知

A study to assess the efficacy of Resveratrol-Copper (R-Cu) in ameliorating toxicity in patients receiving palliative chemotherapy for advanced stage IV inoperable gastric cancers.

TMC Research Administrative Council0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Male or female patients 18 years and
  • 2.Patients who have given written
  • informed consent
  • 3.Patients with performance status of 0, 1 or 2
  • (ECOG scale)
  • 4.Treatment naïve inoperable stage 4
  • adenocarcinoma of the distal stomach in whom
  • the GE junction of the stomach is free of
  • 5.Histologically proven gastric adenocarcinoma;
  • 6.No prior chemotherapy
  • 7. No prior radiotherapy and or surgery
  • 8. Adequate hepatic, renal, and hematologic
  • function at baseline.

排除标准

  • 1.Uncontrolled medical comorbidities like
  • hypertensive, diabetes mellitus, HbsAg and
  • HIV positive, etc.
  • 2.Presence of gastric outlet obstruction
  • 3.Gastro-esophageal junction cancers
  • 4.Significant neuropathy
  • 5.Presence of brain or leptomeningeal
  • 6.Patients taking alternative / complementary

研究者

发起方
TMC Research Administrative Council

相似试验